Related references
Note: Only part of the references are listed.Abnormal effector and regulatory T cell subsets in paediatric-onset multiple sclerosis
Ina Mexhitaj et al.
BRAIN (2019)
Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosis
Marina R. von Essen et al.
BRAIN (2019)
Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis A Randomized Clinical Trial
Richard K. Burt et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Cladribine induces long lasting oligoclonal bands disappearance in relapsing multiple sclerosis patients: 10-year observational study
Konrad Rejdak et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study
Gavin Giovannoni et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study
Gavin Giovannoni et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells
Bryan Ceronie et al.
JOURNAL OF NEUROLOGY (2018)
Defining response profiles after alemtuzumab: Rare paradoxical disease exacerbation
Heinz Wiendl et al.
NEUROLOGY (2018)
Multiple Sclerosis: Mechanisms and Immunotherapy
Clare Baecher-Allan et al.
NEURON (2018)
Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease
Darius Haeusler et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Restoration of regulatory B cell deficiency following alemtuzumab therapy in patients with relapsing multiple sclerosis
Yeseul Kim et al.
JOURNAL OF NEUROINFLAMMATION (2018)
Sarcoidosis following alemtuzumab treatment for multiple sclerosis
Mark D. Willis et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Sarcoidosis following alemtuzumab treatment: Autoimmunity mediated by T cells and interferon-γ
Steffen Pfeuffer
MULTIPLE SCLEROSIS JOURNAL (2018)
Cladribine - an old newcomer for pulsed immune reconstitution in MS
Heinz Wiendl
NATURE REVIEWS NEUROLOGY (2017)
Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis
Paolo A. Muraro et al.
NATURE REVIEWS NEUROLOGY (2017)
Alemtuzumab CARE-MS I 5-year follow-up Durable efficacy in the absence of continuous MS therapy
Eva Havrdova et al.
NEUROLOGY (2017)
High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS
Richard A. Nash et al.
NEUROLOGY (2017)
Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis
Paolo A. Muraro et al.
JAMA NEUROLOGY (2017)
Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases
John A. Snowden et al.
BLOOD ADVANCES (2017)
Both cladribine and alemtuzumab may effect MS via B-cell depletion
David Baker et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2017)
T cell responses in the central nervous system
Thomas Korn et al.
NATURE REVIEWS IMMUNOLOGY (2017)
Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series
Laura Azzopardi et al.
JOURNAL OF NEUROLOGY (2016)
ALAIN01-Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential
Tobias Ruck et al.
BMC NEUROLOGY (2016)
Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial
Harold L. Atkins et al.
LANCET (2016)
The search for the target antigens of multiple sclerosis, part 1: autoreactive CD4+T lymphocytes as pathogenic effectors and therapeutic targets
Reinhard Hohlfeld et al.
LANCET NEUROLOGY (2016)
Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin
Rahul Palchaudhuri et al.
NATURE BIOTECHNOLOGY (2016)
Alemtuzumab long-term immunologic effect Treg suppressor function increases up to 24 months
Stefania De Mercanti et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2016)
Immune reconstitution 20 years after treatment with alemtuzumab in a rheumatoid arthritis cohort: implications for lymphocyte depleting therapies
Faye A. H. Cooles et al.
ARTHRITIS RESEARCH & THERAPY (2016)
Autologous haematopoietic stem cell transplantation reduces abnormalities in the expression of immune genes in multiple sclerosis
Alessandra de Paula A. Sousa et al.
CLINICAL SCIENCE (2015)
Tolerance of activated pathogenic CD4+T cells by transcriptional targeting of dendritic cells
B. de Andrade Pereira et al.
GENE THERAPY (2015)
Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy
Rui Li et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
SCT for severe autoimmune diseases: consensus guidelines of the European Society for Blood and Marrow Transplantation for immune monitoring and biobanking
T. Alexander et al.
BONE MARROW TRANSPLANTATION (2015)
Autologous hematopoietic SCT normalizes miR-16,-155 and-142-3p expression in multiple sclerosis patients
L. C. M. Arruda et al.
BONE MARROW TRANSPLANTATION (2015)
Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy
Orla Tuohy et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2015)
Cladribine Exposure Results in a Sustained Modulation of the Cytokine Response in Human Peripheral Blood Mononuclear Cells
Melanie Korsen et al.
PLOS ONE (2015)
Guiding Postablative Lymphocyte Reconstitution as a Route Toward Transplantation Tolerance
G. Piotti et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2014)
Long-Term Results in Recipients of Combined HLA-Mismatched Kidney and Bone Marrow Transplantation Without Maintenance Immunosuppression
T. Kawai et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2014)
Cladribine exerts an immunomodulatory effect on human and murine dendritic cells
Stefan H. P. Kraus et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2014)
Alemtuzumab-Related Thyroid Dysfunction in a Phase 2 Trial of Patients With Relapsing-Remitting Multiple Sclerosis
Gilbert H. Daniels et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
T cell repertoire following autologous stem cell transplantation for multiple sclerosis
Paolo A. Muraro et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis
Arumugam Palanichamy et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO
Jeffrey M. Gelfand et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2014)
Non-depleting anti-CD4 monoclonal antibody induces immune tolerance to ERT in a murine model of Pompe disease
Baodong Sun et al.
MOLECULAR GENETICS AND METABOLISM REPORTS (2014)
Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation
Peter J. Darlington et al.
ANNALS OF NEUROLOGY (2013)
Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis
Sofia V. Abrahamsson et al.
BRAIN (2013)
Differential Reconstitution of T Cell Subsets following Immunodepleting Treatment with Alemtuzumab (Anti-CD52 Monoclonal Antibody) in Patients with Relapsing-Remitting Multiple Sclerosis
Xin Zhang et al.
JOURNAL OF IMMUNOLOGY (2013)
Cladribine interferes with IL-1β synaptic effects in experimental multiple sclerosis
Alessandra Musella et al.
JOURNAL OF NEUROIMMUNOLOGY (2013)
Impact of cladribine therapy on changes in circulating dendritic cell subsets, T cells and B cells in patients with multiple sclerosis
Krystyna Mitosek-Szewczyk et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2013)
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis
Ashley H. Beecham et al.
NATURE GENETICS (2013)
Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation
Joanne L. Jones et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
A 5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum Disorder
Su-Hyun Kim et al.
JAMA NEUROLOGY (2013)
Rituximab induces sustained reduction of pathogenic B cells in patients with peripheral nervous system autoimmunity
Michael A. Maurer et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells
Tom A. Barr et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Autoimmunity's next top models
Hartmut Wekerle et al.
NATURE MEDICINE (2012)
Cladribine inhibits cytokine secretion by T cells independently of deoxycytidine kinase activity
Bruno Laugel et al.
JOURNAL OF NEUROIMMUNOLOGY (2011)
Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab
H. L. Pellkofer et al.
NEUROLOGY (2011)
Abnormal B-Cell Cytokine Responses A Trigger of T-Cell Mediated Disease in MS?
Amit Bar-Or et al.
ANNALS OF NEUROLOGY (2010)
B-Cell Reconstitution and BAFF After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis
Sara A. J. Thompson et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2010)
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
Gavin Giovannoni et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system
Tobias Alexander et al.
BLOOD (2009)
Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis
T. Kopadze et al.
EUROPEAN JOURNAL OF NEUROLOGY (2009)
Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab
Roberto Stasi et al.
BLOOD (2008)
Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro
Xingmin Feng et al.
BLOOD (2008)
Bone-marrow transplantation fails to halt intrathecal lymphocyte activation in multiple sclerosis
T. Mondria et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2008)
Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis
Birgit Obermeier et al.
NATURE MEDICINE (2008)
B-cell depletion with Rituximab in relapsing-remitting multiple sclerosis
Stephen L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis
Martin Duddy et al.
JOURNAL OF IMMUNOLOGY (2007)
Heterogeneous CD52 expression among hematologic neoplasms: Implications for the use of alemtuzumab (CAMPATH-1H)
Scott J. Rodig et al.
CLINICAL CANCER RESEARCH (2006)
Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients
Anne H. Cross et al.
JOURNAL OF NEUROIMMUNOLOGY (2006)
Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients
PA Muraro et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis
J Moore et al.
ARTHRITIS AND RHEUMATISM (2002)
MRI and CSF oligoclonal bands after autologous hematopoietic stem cell transplantation in MS
A Saiz et al.
NEUROLOGY (2001)
Clonal expansions of CD8+ T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction
H Babbe et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Autologous stem cell transplantation in progressive multiple sclerosis - An interim analysis of efficacy
A Fassas et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2000)
Share Paper
